Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB), for alleged violations of the federal securities laws. Investors who purchased or otherwise acquired shares between January 29, 2015 and July 23, 2015, inclusive (the “Class Period”), have until October 19, 2015 to serve as lead plaintiff in the class action.

If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the complaint, the Company misrepresented the financial benefits that it would receive from the sale of its drug TECFIDERA. On multiple occasions during the first half of 2015, the Company predicted 2015 revenue growth between 14% and 16% over 2014. Biogen had touted TECFIDERA as a very large contributor to their overall revenue growth. When the truth was revealed, shares dropped causing investors harm.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.